<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR89420-0084 </DOCNO><DOCID>fr.4-20-89.f2.A1083</DOCID><TEXT><ITAG tagnum="69"><ITAG tagnum="18">Food and Drug Administration</ITAG><ITAG tagnum="52">Advisory Committee: Meeting</ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>This notice announces a forthcoming meeting of a publicadvisory committee of the Food and Drug Administration (FDA). This noticealso summarizes the procedures for the meeting and methods by which interestedpersons may participate in open public hearings before FDA's advisory committees.<T3>Meeting: </T3>The following advisory committee meeting is announced:<ITAG tagnum="84">Dermatologic Drugs Advisory Committee</ITAG><T3>Date, time, and place. </T3>May 8, 1989, 8:30 a.m., Conference Rms.D and E, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD. <T3>Type of meeting and contact person. </T3>Open public hearing, 8:30a.m. to 9:30 a.m., unless public participation does not last that long;open committee discussion, 9:30 a.m. to 12:30 p.m.; closed committee deliberations,1:30 p.m. to 5 p.m.; Isaac F. Roubein, Center for Drug Evaluation and Research(HFD-9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD20857, 301-443-4695.<T3>General function of the committee: </T3>The committee reviews and evaluatesavailable data on the safety and effectiveness of marketed and investigationalhuman drugs for use in the treatment of dermatologic disorders.<T3>Agenda-Open public hearing. </T3>Interested persons requesting to presentdata, information, or views, orally or in writing, on issues pending beforethe committee, should communicate with the committee contact person.<T3>Open committee discussion.</T3> The committee will discuss the currentstatus of isotretinoin, Accutane<T4>#, </T4>Hoffman-LaRoche, Inc. <T3>Closed committee deliberations.</T3> The committee will discuss tradesecret and/or confidential commercial information relevant to pending investigationalnew drug number 29-951 and new drug application number 19-795. This portionof the meeting will be closed to permit discussion of this information(5 U.S.C. 552b(c)(4)).Each public advisory committee meeting listed above may have as many asfour separable portions: (1) An open public hearing, (2) an open committeediscussion, (3) a closed presentation of data, and (4) a closed committeedeliberation. Every advisory committee meeting shall have an open publichearing portion. Whether or not it also includes any of the other threeportions will depend upon the specific meeting involved. The dates andtimes reserved for the separate portions of each committee meeting arelisted above.The open public hearing portion of each meeting shall be at least 1 hourlong unless public participation does not last that long. It is emphasized,however, that the 1 hour time limit for an open public hearing representsa minimum rather than a maximum time for public participation, and an openpublic hearing may last for whatever longer period the committee chairpersondetermines will facilitate the committee's work.Public hearings are subject to FDA's guidelines (Subpart C of 21 CFR Part10) concerning the policy and procedures for electronic media coverageof FDA's public administrative proceedings, including hearings before publicadvisory committees under 21 CFR Part 14. Under 21 CFR 10.205, representativesof the electronic media may be permitted, subject to certain limitations,to videotape, film, or otherwise record FDA's public administrative proceedings,including presentations by participants.Meetings of advisory committees shall be conducted, insofar as is practical,in accordance with the agenda published in this <T4>Federal Register </T4>notice. Changes in the agenda will be announcedat the beginning of the open portion of a meeting.Any interested person who wishes to be assured of the right to make anoral presentation at the open public hearing portion of a meeting shallinform the contact person listed above, either orally or in writing, priorto the meeting. Any person attending the hearing who does not in advanceof the meeting request an opportunity to speak will be allowed to makean oral presentation at the hearing's conclusion, if time permits, at thechairperson's discretion.Persons interested in specific agenda items to be discussed in open sessionmay ascertain from the contact person the approximate time of discussion.Details on the agenda, questions to be addressed by the committee, anda current list of committee members are available from the contact personbefore and after the meeting. Transcripts of the open portion of the meetingwill be available from the Freedom of Information Office (HFI-35), Foodand Drug Administration, Rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857,approximately 15 working days after the meeting, at a cost of 10 centsper page. The transcript may be viewed at the Dockets Management Branch(HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville,MD 20857, approximately 15 working days after the meeting, between thehours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of theopen portion of the meeting will be available from the Freedom of InformationOffice (address above) beginning approximately 90 days after the meeting.The Commissioner, with the concurrence of the Chief Counsel, has determinedfor the reasons stated that those portions of the advisory committee meetingsso designated in this notice shall be closed. The Federal Advisory CommtiteeAct (FACA), as amended by the Government in the Sunshine Act (Pub. L. 94-409),permits such closed advisory committee meetings in certain circumstances.Those portions of a meeting designated as closed, however, shall be closedfor the shortest possible time, consistent with the intent of the citedstatutes.The FACA, as amended, provides that a portion of a meeting may be closedwhere the matter for discussion involves a trade secret; commercial orfinancial information that is privileged or confidential; information ofa personal nature, disclosure of which would be a clearly unwarranted invasionof personal privacy; investigatory files compiled for law enforcement purposes;information the premature disclosure of which would be likely to significantlyfrustrate implementation of a proposed agency action; and information incertain other instances not generally relevant to FDA matters.Examples of portions of FDA advisory committee meetings that ordinarilymay be closed, where necessary and in accordance with FACA criteria, includethe review, discussion, and evaluation of drafts of regulations or guidelinesor similar preexisting internal agency documents, but only if their prematuredisclosure is likely to significantly frustrate implementation of proposedagency action; review of trade secrets and confidential commercial or financialinformation submitted to the agency; consideration of matters involvinginvestigatory files compiled for law enforcement purposes; and review ofmatters, such as personnel records or individual patient records, wheredisclosure would constitute a clearly unwarranted invasion of personalprivacy.Examples of portions of FDA advisory committee meetings that ordinarilyshall not be closed include the review, discussion, and evaluation of generalpreclinical and clinical test protocols and procedures for a class of drugsor devices; consideration of labeling requirements for a class of marketeddrugs or devices; review of data and information on specific investigationalor marketed drugs and devices tha have previously been made public; presentationof any other data or information that is not exempt from public disclosurepursuant to the FACA, as amended; and, notably deliberative sessions toformulate advice and recommendations to the agency on matters that do notindependently justify closing.This notice is issued under section 10 (a)(1) and (2) of the Federal AdvisoryCommittee Act (Pub. L. 92-463, 86 Stat. 770-776 (5 U.S.C. App. I)), andFDA's regulations (21 CFR Part 14) on advisory committees.<ITAG tagnum="21">Dated: April 14, 1989.</ITAG><ITAG tagnum="6">Frank E. Young,</ITAG><ITAG tagnum="4">Commissioner of Food and Drugs.</ITAG><ITAG tagnum="40">[FR Doc. 89-9415 Filed 4-19-89; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></TEXT></DOC>